Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CATX NASDAQ:INMD NASDAQ:IRMD NASDAQ:PLSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.23-4.2%$3.74$1.60▼$16.19$239.87M1.2919,189 shs688,986 shsINMDInMode$15.02-0.3%$14.53$13.14▼$19.85$952.56M2951,671 shs1.24 million shsIRMDiRadimed$71.52-0.5%$65.63$45.89▼$74.00$914.09M1.0243,975 shs38,834 shsPLSEPulse Biosciences$14.77-1.1%$15.49$13.77▼$25.00$1.01B1.68150,342 shs341,300 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics-1.75%+1.51%-8.42%+2.74%-78.41%INMDInMode-1.37%+4.58%+6.80%+5.53%-2.90%IRMDiRadimed+0.06%+0.36%+2.80%+19.80%+59.76%PLSEPulse Biosciences-0.66%-1.13%+1.56%-10.70%-14.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.23-4.2%$3.74$1.60▼$16.19$239.87M1.2919,189 shs688,986 shsINMDInMode$15.02-0.3%$14.53$13.14▼$19.85$952.56M2951,671 shs1.24 million shsIRMDiRadimed$71.52-0.5%$65.63$45.89▼$74.00$914.09M1.0243,975 shs38,834 shsPLSEPulse Biosciences$14.77-1.1%$15.49$13.77▼$25.00$1.01B1.68150,342 shs341,300 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics-1.75%+1.51%-8.42%+2.74%-78.41%INMDInMode-1.37%+4.58%+6.80%+5.53%-2.90%IRMDiRadimed+0.06%+0.36%+2.80%+19.80%+59.76%PLSEPulse Biosciences-0.66%-1.13%+1.56%-10.70%-14.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCATXPerspective Therapeutics 3.18Buy$12.56288.72% UpsideINMDInMode 2.13Hold$18.0420.12% UpsideIRMDiRadimed 3.00Buy$72.000.67% UpsidePLSEPulse Biosciences 3.00Buy$22.0048.95% UpsideCurrent Analyst Ratings BreakdownLatest CATX, PLSE, INMD, and IRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025INMDInModeNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold7/30/2025INMDInModeBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$24.00 ➝ $21.007/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/11/2025INMDInModeCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$15.007/7/2025PLSEPulse BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$22.006/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/AINMDInMode$394.82M2.40$1.82 per share8.26$10.12 per share1.48IRMDiRadimed$73.24M12.42$1.57 per share45.44$6.85 per share10.44PLSEPulse Biosciences$700K1,420.03N/AN/A$1.87 per share7.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%11/11/2025 (Estimated)INMDInMode$181.27M$2.476.088.25N/A44.50%18.38%16.35%10/29/2025 (Estimated)IRMDiRadimed$19.23M$1.6244.1535.76N/A26.61%23.30%20.62%10/30/2025 (Estimated)PLSEPulse Biosciences-$53.58M-$1.05N/A∞N/AN/A-63.19%-54.98%10/29/2025 (Estimated)Latest CATX, PLSE, INMD, and IRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025PLSEPulse Biosciences-$0.26-$0.28-$0.02-$0.28$0.50 millionN/A7/30/2025Q2 2025INMDInMode$0.50$0.47-$0.03$0.42$98.45 million$95.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCATXPerspective TherapeuticsN/AN/AN/AN/AN/AINMDInModeN/AN/AN/AN/AN/AIRMDiRadimed$0.680.96%N/A41.98%1 YearsPLSEPulse BiosciencesN/AN/AN/AN/AN/ALatest CATX, PLSE, INMD, and IRMD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/31/2025IRMDiRadimedquarterly$0.171.13%8/18/20258/18/20258/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCATXPerspective TherapeuticsN/A9.609.60INMDInModeN/A9.608.58IRMDiRadimedN/A8.787.51PLSEPulse BiosciencesN/A12.0512.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCATXPerspective Therapeutics54.66%INMDInMode68.04%IRMDiRadimed92.34%PLSEPulse Biosciences76.95%Insider OwnershipCompanyInsider OwnershipCATXPerspective Therapeutics3.52%INMDInMode6.92%IRMDiRadimed36.80%PLSEPulse Biosciences74.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCATXPerspective Therapeutics7074.26 million65.21 millionOptionableINMDInMode48063.21 million58.84 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionablePLSEPulse Biosciences14067.30 million17.09 millionOptionableCATX, PLSE, INMD, and IRMD HeadlinesRecent News About These CompaniesPulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual MeetingSeptember 10 at 3:43 PM | finance.yahoo.comPulse Biosciences Gains FDA Approval for NANOCLAMP StudySeptember 9 at 10:58 AM | msn.comPulse Biosciences granted FDA approval for investigational device exemptionSeptember 8 at 11:54 AM | msn.comPulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial FibrillationSeptember 8 at 11:54 AM | finance.yahoo.comPulse Biosciences wins FDA IDE to conduct study of PFA tech for AFibSeptember 8 at 11:54 AM | massdevice.comPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | businesswire.comNuveen LLC Invests $915,000 in Pulse Biosciences, Inc $PLSESeptember 4, 2025 | marketbeat.comPulse Biosciences Announces Success in Thyroid StudySeptember 3, 2025 | msn.comPulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) StudySeptember 2, 2025 | joplinglobe.comJPLSE Shares Rise on First-in-Human Data for Thyroid Nodule TreatmentAugust 27, 2025 | zacks.comPulse Biosciences reports first-in-human data for PFA to treat benign thyroid nodulesAugust 27, 2025 | massdevice.comPulse Biosciences (NASDAQ:PLSE) Trading Down 5.2% - Time to Sell?August 17, 2025 | marketbeat.comPulse Biosciences (NASDAQ:PLSE) Trading Up 7.1% - What's Next?August 15, 2025 | marketbeat.comPulse Biosciences (NASDAQ:PLSE) Releases Earnings ResultsAugust 14, 2025 | marketbeat.comPulse Biosciences Reports Q2 2025 Progress and ResultsAugust 13, 2025 | msn.comPulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comPulse Biosciences Reports Business Updates and Second Quarter 2025 Financial ResultsAugust 12, 2025 | businesswire.comPandora Wealth Inc. Takes Position in Pulse Biosciences, Inc (NASDAQ:PLSE)August 10, 2025 | marketbeat.comPulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth ConferenceAugust 1, 2025 | finance.yahoo.comPulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025July 29, 2025 | businesswire.comOppenheimer Initiates Coverage of Pulse Biosciences (PLSE) with Outperform RecommendationJuly 8, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCATX, PLSE, INMD, and IRMD Company DescriptionsPerspective Therapeutics NYSE:CATX$3.23 -0.14 (-4.15%) Closing price 04:00 PM EasternExtended Trading$3.26 +0.03 (+0.93%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.InMode NASDAQ:INMD$15.02 -0.05 (-0.33%) Closing price 04:00 PM EasternExtended Trading$15.03 +0.01 (+0.07%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.iRadimed NASDAQ:IRMD$71.52 -0.37 (-0.51%) Closing price 04:00 PM EasternExtended Trading$71.60 +0.09 (+0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Pulse Biosciences NASDAQ:PLSE$14.77 -0.17 (-1.14%) Closing price 04:00 PM EasternExtended Trading$14.30 -0.47 (-3.18%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
